<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054729</url>
  </required_header>
  <id_info>
    <org_study_id>P7977-0221</org_study_id>
    <nct_id>NCT01054729</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients</brief_title>
  <official_title>A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with genotype 1 HCV infection were randomized to 1 of 3 sofosbuvir doses (100
      mg, 200 mg, or 400 mg) or matching placebo once daily based upon stratification for IL28B
      status (CC or CT/TT). Placebo tablets were administered to participants receiving 100 mg
      active sofosbuvir (3 placebo tablets) and 200 mg active sofosbuvir (2 placebo tablets) in
      order to maintain the study blind. Participants received sofosbuvir/matching placebo from Day
      0 to 27. Participants also received treatment with PEG+RBV starting on Day 0 of the study
      which continued for 48 weeks. Participants were evaluated for sustained virologic response
      (SVR) for an additional 24 weeks following completion of study treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Adverse events (AEs) occurring during the sofosbuvir treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating HCV RNA at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Rapid virologic response (RVR) was defined as HCV RNA below the limit of detection (LOD [15 IU/mL]) at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</measure>
    <time_frame>Post-treatment Weeks 12 and 24</time_frame>
    <description>SVR at 12 weeks (SVR12) and 24 weeks (SVR24) was defined as HCV RNA &lt; LOD 12 and 24 weeks after last dose of PEG+RBV, respectively, following completion of 48 weeks of treatment (4 weeks of sofosbuvir or matching placebo and PEG+RBV, followed by an additional 44 weeks of PEG+RBV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The Cmax of sofosbuvir was measured at Day 0 following a single dose of sofosbuvir.
Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
    <description>The Cmax of sofosbuvir was measured at Day 27 following continuous dosing of sofosbuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The AUCinf of sofosbuvir was analyzed at Day 0 (following a single dose of sofosbuvir).
AUCinf is defined as the concentration of drug (area under the plasma concentration versus time curve) extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
    <description>The AUCtau of sofosbuvir was analyzed at Day 27 (following continuous dosing of sofosbuvir).
AUCtau is defined as the concentration of drug (area under the plasma concentration versus time curve) over the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The Cmax of GS-331007 was measured at Day 0 following a single dose of sofosbuvir. GS-331007 is the predominant circulating metabolite of sofosbuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
    <description>The Cmax of GS-331007 was measured at Day 27 following continuous dosing of sofosbuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The AUCinf of GS-331007 was analyzed at Day 0 (following a single dose of sofosbuvir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
    <description>The AUCtau of GS-331007 was analyzed at Day 27 (following continuous dosing of sofosbuvir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The Cmax of GS-566500 was measured at Day 0 following a single dose of sofosbuvir. GS-566500 is one of the major metabolites of sofosbuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
    <description>The Cmax of GS-566500 was measured at Day 27 following continuous dosing of sofosbuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The AUCinf of GS-566500 was analyzed at Day 0 (following a single dose of sofosbuvir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
    <description>The AUCtau of GS-566500 was analyzed at Day 27 (following continuous dosing of sofosbuvir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir 100 mg+PEG+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir 200 mg+PEG+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir 400 mg+PEG+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+PEG+RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir tablet(s) administered orally once daily</description>
    <arm_group_label>Sofosbuvir 100 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Sofosbuvir 200 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Sofosbuvir 400 mg+PEG+RBV</arm_group_label>
    <other_name>Sovaldi®</other_name>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match sofosbuvir administered orally once daily</description>
    <arm_group_label>Placebo+PEG+RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.</description>
    <arm_group_label>Sofosbuvir 100 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Sofosbuvir 200 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Sofosbuvir 400 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Placebo+PEG+RBV</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg).</description>
    <arm_group_label>Sofosbuvir 100 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Sofosbuvir 200 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Sofosbuvir 400 mg+PEG+RBV</arm_group_label>
    <arm_group_label>Placebo+PEG+RBV</arm_group_label>
    <other_name>Copegus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naive males and females, 18-65 years of age

          -  Genotype 1 HCV infection

          -  Negative pregnancy test for females of childbearing age

          -  Females of childbearing age and males with female partners of childbearing age must
             use two forms of contraception during treatment and following the last dose of
             ribavirin in accordance with locally approved label for ribavirin

        Exclusion Criteria:

          -  Hepatitis B or HIV infection

          -  Pregnant or breast feeding females or male partners of pregnant females

          -  Previous interferon or ribavirin-based therapy or investigational anti-HCV agent

          -  History or evidence of medical condition associated with chronic liver disease other
             than HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H. Hyland, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>January 6, 2014</results_first_submitted>
  <results_first_submitted_qc>January 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2014</results_first_posted>
  <disposition_first_submitted>May 24, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 31, 2012</disposition_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C infection Genotype 1</keyword>
  <keyword>HCV</keyword>
  <keyword>GT1</keyword>
  <keyword>GT 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at a total of 7 study sites in the United States. The first participant was screened on 18 January 2010. The last participant observation was on 25 August 2011.</recruitment_details>
      <pre_assignment_details>143 participants were screened and 64 were randomized; 63 participants were treated, and comprise the Safety Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sofosbuvir 100 mg+PEG+RBV</title>
          <description>Participants received sofosbuvir 100 mg for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
        </group>
        <group group_id="P2">
          <title>Sofosbuvir 200 mg+PEG+RBV</title>
          <description>Participants received sofosbuvir 200 mg for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
        </group>
        <group group_id="P3">
          <title>Sofosbuvir 400 mg+PEG+RBV</title>
          <description>Participants received sofosbuvir 400 mg for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
        </group>
        <group group_id="P4">
          <title>Placebo+PEG+RBV</title>
          <description>Participants received placebo to match sofosbuvir for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up, Later Contacted Site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-responder</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PEG/RBV Non-responder</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal/Obligations</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who were randomized and treated were analyzed for Baseline Characteristics</population>
      <group_list>
        <group group_id="B1">
          <title>Sofosbuvir 100 mg+PEG+RBV</title>
          <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sofosbuvir 200 mg+PEG+RBV</title>
          <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Sofosbuvir 400 mg+PEG+RBV</title>
          <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo+PEG+RBV</title>
          <description>Placebo to match sofosbuvir for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="10.10"/>
                    <measurement group_id="B2" value="44.4" spread="8.34"/>
                    <measurement group_id="B3" value="44.9" spread="8.43"/>
                    <measurement group_id="B4" value="46.6" spread="11.44"/>
                    <measurement group_id="B5" value="45.0" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C (HCV) RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.64" spread="0.476"/>
                    <measurement group_id="B2" value="6.28" spread="0.813"/>
                    <measurement group_id="B3" value="6.49" spread="0.602"/>
                    <measurement group_id="B4" value="6.48" spread="0.666"/>
                    <measurement group_id="B5" value="6.47" spread="0.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA Level (IU/mL)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 800,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 800,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver Biopsy Fibrosis Score</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None or Minimal Fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portal Fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bridging Fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cirrhosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="29.69"/>
                    <measurement group_id="B2" value="72.6" spread="46.45"/>
                    <measurement group_id="B3" value="95.4" spread="75.86"/>
                    <measurement group_id="B4" value="70.0" spread="40.73"/>
                    <measurement group_id="B5" value="76.2" spread="50.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28b Genotype</title>
          <description>CC, CT, and TT alleles are different forms of the IL28b gene.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT/TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</title>
        <description>Adverse events (AEs) occurring during the sofosbuvir treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Safety Analysis Set: participants were randomized and received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo+PEG+RBV</title>
            <description>Placebo to match sofosbuvir for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</title>
          <description>Adverse events (AEs) occurring during the sofosbuvir treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.</description>
          <population>Safety Analysis Set: participants were randomized and received at least 1 dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="86.7"/>
                    <measurement group_id="O4" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or higher AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to drug discontinuation/interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating HCV RNA at Week 4</title>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo+PEG+RBV</title>
            <description>Placebo to match sofosbuvir for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating HCV RNA at Week 4</title>
          <population>Safety Analysis Set</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.323" spread="0.6642"/>
                    <measurement group_id="O2" value="-5.081" spread="0.8068"/>
                    <measurement group_id="O3" value="-5.346" spread="0.6130"/>
                    <measurement group_id="O4" value="-2.8" spread="1.6034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rapid Virologic Response at Week 4</title>
        <description>Rapid virologic response (RVR) was defined as HCV RNA below the limit of detection (LOD [15 IU/mL]) at Week 4.</description>
        <time_frame>Week 4</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo+PEG+RBV</title>
            <description>Placebo to match sofosbuvir for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Virologic Response at Week 4</title>
          <description>Rapid virologic response (RVR) was defined as HCV RNA below the limit of detection (LOD [15 IU/mL]) at Week 4.</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="94.4"/>
                    <measurement group_id="O3" value="93.3"/>
                    <measurement group_id="O4" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</title>
        <description>SVR at 12 weeks (SVR12) and 24 weeks (SVR24) was defined as HCV RNA &lt; LOD 12 and 24 weeks after last dose of PEG+RBV, respectively, following completion of 48 weeks of treatment (4 weeks of sofosbuvir or matching placebo and PEG+RBV, followed by an additional 44 weeks of PEG+RBV).</description>
        <time_frame>Post-treatment Weeks 12 and 24</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo+PEG+RBV</title>
            <description>Placebo to match sofosbuvir for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</title>
          <description>SVR at 12 weeks (SVR12) and 24 weeks (SVR24) was defined as HCV RNA &lt; LOD 12 and 24 weeks after last dose of PEG+RBV, respectively, following completion of 48 weeks of treatment (4 weeks of sofosbuvir or matching placebo and PEG+RBV, followed by an additional 44 weeks of PEG+RBV).</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="72.2"/>
                    <measurement group_id="O3" value="86.7"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="80.0"/>
                    <measurement group_id="O4" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</title>
        <description>The Cmax of sofosbuvir was measured at Day 0 following a single dose of sofosbuvir.
Cmax is defined as the maximum concentration of drug.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</title>
          <description>The Cmax of sofosbuvir was measured at Day 0 following a single dose of sofosbuvir.
Cmax is defined as the maximum concentration of drug.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.08" spread="181.54"/>
                    <measurement group_id="O2" value="332.26" spread="215.53"/>
                    <measurement group_id="O3" value="1257.50" spread="736.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</title>
        <description>The Cmax of sofosbuvir was measured at Day 27 following continuous dosing of sofosbuvir.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</title>
          <description>The Cmax of sofosbuvir was measured at Day 27 following continuous dosing of sofosbuvir.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.54" spread="171.10"/>
                    <measurement group_id="O2" value="475.14" spread="358.88"/>
                    <measurement group_id="O3" value="1355.65" spread="853.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</title>
        <description>The AUCinf of sofosbuvir was analyzed at Day 0 (following a single dose of sofosbuvir).
AUCinf is defined as the concentration of drug (area under the plasma concentration versus time curve) extrapolated to infinite time.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</title>
          <description>The AUCinf of sofosbuvir was analyzed at Day 0 (following a single dose of sofosbuvir).
AUCinf is defined as the concentration of drug (area under the plasma concentration versus time curve) extrapolated to infinite time.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.19" spread="199.54"/>
                    <measurement group_id="O2" value="585.56" spread="342.53"/>
                    <measurement group_id="O3" value="1867.24" spread="959.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</title>
        <description>The AUCtau of sofosbuvir was analyzed at Day 27 (following continuous dosing of sofosbuvir).
AUCtau is defined as the concentration of drug (area under the plasma concentration versus time curve) over the dosing interval.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</title>
          <description>The AUCtau of sofosbuvir was analyzed at Day 27 (following continuous dosing of sofosbuvir).
AUCtau is defined as the concentration of drug (area under the plasma concentration versus time curve) over the dosing interval.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.70" spread="203.13"/>
                    <measurement group_id="O2" value="732.27" spread="297.19"/>
                    <measurement group_id="O3" value="2011.23" spread="988.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</title>
        <description>The Cmax of GS-331007 was measured at Day 0 following a single dose of sofosbuvir. GS-331007 is the predominant circulating metabolite of sofosbuvir.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</title>
          <description>The Cmax of GS-331007 was measured at Day 0 following a single dose of sofosbuvir. GS-331007 is the predominant circulating metabolite of sofosbuvir.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.32" spread="88.68"/>
                    <measurement group_id="O2" value="357.33" spread="99.88"/>
                    <measurement group_id="O3" value="662.13" spread="214.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</title>
        <description>The Cmax of GS-331007 was measured at Day 27 following continuous dosing of sofosbuvir.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</title>
          <description>The Cmax of GS-331007 was measured at Day 27 following continuous dosing of sofosbuvir.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.79" spread="105.02"/>
                    <measurement group_id="O2" value="357.38" spread="109.91"/>
                    <measurement group_id="O3" value="717.23" spread="208.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</title>
        <description>The AUCinf of GS-331007 was analyzed at Day 0 (following a single dose of sofosbuvir).</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</title>
          <description>The AUCinf of GS-331007 was analyzed at Day 0 (following a single dose of sofosbuvir).</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2173.18" spread="852.32"/>
                    <measurement group_id="O2" value="3984.88" spread="895.69"/>
                    <measurement group_id="O3" value="7559.91" spread="3065.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</title>
        <description>The AUCtau of GS-331007 was analyzed at Day 27 (following continuous dosing of sofosbuvir).</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</title>
          <description>The AUCtau of GS-331007 was analyzed at Day 27 (following continuous dosing of sofosbuvir).</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2256.81" spread="982.40"/>
                    <measurement group_id="O2" value="3389.23" spread="832.01"/>
                    <measurement group_id="O3" value="7398.99" spread="2633.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</title>
        <description>The Cmax of GS-566500 was measured at Day 0 following a single dose of sofosbuvir. GS-566500 is one of the major metabolites of sofosbuvir.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</title>
          <description>The Cmax of GS-566500 was measured at Day 0 following a single dose of sofosbuvir. GS-566500 is one of the major metabolites of sofosbuvir.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.99" spread="35.98"/>
                    <measurement group_id="O2" value="145.51" spread="31.95"/>
                    <measurement group_id="O3" value="293.35" spread="92.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</title>
        <description>The Cmax of GS-566500 was measured at Day 27 following continuous dosing of sofosbuvir.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</title>
          <description>The Cmax of GS-566500 was measured at Day 27 following continuous dosing of sofosbuvir.</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.75" spread="38.51"/>
                    <measurement group_id="O2" value="132.72" spread="49.33"/>
                    <measurement group_id="O3" value="237.46" spread="51.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</title>
        <description>The AUCinf of GS-566500 was analyzed at Day 0 (following a single dose of sofosbuvir).</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</title>
          <description>The AUCinf of GS-566500 was analyzed at Day 0 (following a single dose of sofosbuvir).</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.22" spread="122.40"/>
                    <measurement group_id="O2" value="645.95" spread="228.09"/>
                    <measurement group_id="O3" value="1315.94" spread="618.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</title>
        <description>The AUCtau of GS-566500 was analyzed at Day 27 (following continuous dosing of sofosbuvir).</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose)</time_frame>
        <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</title>
          <description>The AUCtau of GS-566500 was analyzed at Day 27 (following continuous dosing of sofosbuvir).</description>
          <population>Participants in the Safety Analysis Set with available data and who received a regimen containing sofosbuvir were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.00" spread="120.64"/>
                    <measurement group_id="O2" value="571.95" spread="156.59"/>
                    <measurement group_id="O3" value="1072.91" spread="327.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Developed Resistance to Sofosbuvir</title>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Participants in the Safety Analysis Set who received a regimen containing sofosbuvir were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sofosbuvir 100 mg+PEG+RBV</title>
            <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sofosbuvir 200 mg+PEG+RBV</title>
            <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sofosbuvir 400 mg+PEG+RBV</title>
            <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Developed Resistance to Sofosbuvir</title>
          <population>Participants in the Safety Analysis Set who received a regimen containing sofosbuvir were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 48</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sofosbuvir 100 mg+PEG+RBV</title>
          <description>Sofosbuvir 100 mg for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sofosbuvir 200 mg+PEG+RBV</title>
          <description>Sofosbuvir 200 mg for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="E3">
          <title>Sofosbuvir 400 mg+PEG+RBV</title>
          <description>Sofosbuvir 400 mg for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo+PEG+RBV</title>
          <description>Placebo to match sofosbuvir for 28 days plus PEG+RBV for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presbyopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Retinal vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Daydreaming</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences, Inc.</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

